to quarter conference the and always, good second call. as to XXXX afternoon and Tim, you, welcome everyone, Thank Relmada
by program MDD provide we the in as that I then quarter is for followed a REL-XXXX Relmada's or first depressive I am major review of pleased questions. second to today And financial you update, our take will ongoing results. planned. will brief proceeding your disorder with Phase report X
MDD. treatment REL-XXXX on as an As for Relmada developing focused is reminder, a adjunctive
made REL-XXXX critical X-arm as study to clinical across have evaluating ongoing Phase adjunctive we communicated, XXX XX to protocol XXX changes MDD. implemented amended rely be at for the previously As sites. study X all our a milligrams pivotal continues to placebo-controlled The
The significantly site. burden by to removing was time duplicative achieved spent side at required in reducing from subjects had exploratory subject from studies. controlled learning seen the both and completed amended optimizes protocol by leverages development lessened This placebo that these of response and our the programs evaluation reduction assessment interest. trials the amendment The the the by were protocol in RELIANCE the potential completed high for and
over we progress. updated continues enrollment the months, next As several will trial you on keep the
XXX, that Relight We Study approximately XXX XXX patients II patients. are we currently trial expect in for planning to first the half a commenced enrollment that enroll newly approximately be initiated of XXX also has XXXX. RELIANCE and completed has Screening to Study named planned the which of
MDD the to Completion and study is to to studies for REL-XXXX XX change evaluating XXXX. adjunctive REL-XXXX treatment the Like safety II, second this trial, is of as half of of Relight randomized, the X-week in a RELIANCE double-blind, placebo-controlled efficacy currently an anticipated of response The day from total ongoing inadequate background experiencing compared treatment. endpoint of baseline both patients score same. in is antidepressant placebo. as primary MDRAS the in The
We Relight for participating the recently emphasize time Phase been with X of sites successful sites the quality has to and meetings designed the at both investigator spent reduce studies. had enrollment. patient
quality appropriate placebo and meetings, intensive focused for the our greater enrollment, training. topics on response controlling data strategies providing and subject team training During investigator on including
quarter. purpose exposure the of expect available to for The open-label these and the required necessary filing, the long-term study with X-year NDA data current during concluded the has of safety the XXX we be Study for safety REL-XXXX, attainment
for plan continue product multiple candidate. we further over on next we'll several late-stage in As to our X including the presentation presence conferences few also of of important To at a development execute months remain end, data and Phase the enhancing support published posters. focused of on the presented REL-XXXX, this clinical plethora scientific we have the significant
posters expect We among in the at XXth scientific XXXX. Barcelona, to in Annual present second other two half of in October Congress ECNP conferences the
addition, In the translational REL-XXXX, published recently potential journal data human abuse in were peer-reviewed psychiatrists.
execute to Maged review data for to reach will detailed I that like funded X provide but to a and would remains RELIANCE trials, emphasize Moving Phase readouts of both fully financials, our our sufficiently Relmada II Relight. on plans
financial to quarter results. will our to Maged? Maged over review turn I the second now call
